S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
NASDAQ:TXMD

TherapeuticsMD (TXMD) Stock Price, News & Analysis

$2.54
+0.14 (+5.83%)
(As of 03/1/2024 ET)
Today's Range
$2.39
$2.59
50-Day Range
$2.23
$2.54
52-Week Range
$1.95
$5.03
Volume
72,777 shs
Average Volume
16,046 shs
Market Capitalization
$26.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TherapeuticsMD MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of TherapeuticsMD in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$33,495 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

794th out of 957 stocks

Pharmaceutical Preparations Industry

365th out of 439 stocks


TXMD stock logo

About TherapeuticsMD Stock (NASDAQ:TXMD)

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Stock Price History

TXMD Stock News Headlines

TherapeuticsMD Inc TXMD
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TherapeuticsMD to Consider Strategic Alternatives
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
TheraputicsMD sells products rights for $153 million
See More Headlines
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/01/2024
Next Earnings (Estimated)
4/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
1
Year Founded
N/A

Profitability

Net Income
$112 million
Pretax Margin
60.97%

Debt

Sales & Book Value

Annual Sales
$69.96 million
Book Value
$3.73 per share

Miscellaneous

Free Float
10,453,000
Market Cap
$26.87 million
Optionable
Optionable
Beta
1.02
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














TXMD Stock Analysis - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings
or view top-rated stocks.

How have TXMD shares performed in 2024?

TherapeuticsMD's stock was trading at $2.25 on January 1st, 2024. Since then, TXMD stock has increased by 12.9% and is now trading at $2.54.
View the best growth stocks for 2024 here
.

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 5th 2024.
View our TXMD earnings forecast
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.17. The business had revenue of $0.44 million for the quarter. TherapeuticsMD had a trailing twelve-month return on equity of 133.83% and a net margin of 47.29%.

When did TherapeuticsMD's stock split?

Shares of TherapeuticsMD reverse split on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by many different institutional and retail investors. Top institutional investors include ADAR1 Capital Management LLC (2.57%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXMD) was last updated on 3/1/2024 by MarketBeat.com Staff